AML

MEDIA ALERT: Wolters Kluwer launches cloud-based AML module for CCH iFirm® in the U.K.

Retrieved on: 
Monday, March 11, 2024
Data Management, Technology, Digital Cash Management, Digital Assets, Data Analytics, Apps, Applications, Payments, Other Professional Services, Legal, Business, Fintech, Blockchain, Finance, Consulting, Security, Accounting, Professional Services, Other Technology, Software, Networks, Internet, Product management, KYC, CCH, Facial recognition, AML, Cryptocurrency

Wolters Kluwer Tax & Accounting (TAA) U.K. has released an anti-money laundering module (AML) within CCH iFirm ®, its cloud-based practice management and compliance software platform.

Key Points: 
  • Wolters Kluwer Tax & Accounting (TAA) U.K. has released an anti-money laundering module (AML) within CCH iFirm ®, its cloud-based practice management and compliance software platform.
  • Wolters Kluwer CCH iFirm AML seamlessly integrates with CCH Central, Wolters Kluwer TAA’s on-premise system, reducing the need to rekey data into a separate system and helping to speed up the AML compliance process and client onboarding.
  • CCH iFirm AML helps to transform the way companies manage their AML duties, helping them mitigate the risks associated with poor AML and KYC practices,” said Natasha Chryssafi, Director of Product Management, Wolters Kluwer TAA U.K.
    As a cloud-based solution CCH iFirm AML provides accounting practices with the flexibility to manage AML compliance from anywhere at any time.
  • Natasha Chryssafi , Product Director, Wolters Kluwer TAA U.K.
    Ben Cunliffe , Senior Product Manager, Wolters Kluwer TAA U.K.

Delta-Fly Pharma Inc.: FDA submission of the protocol of the Phase I/II study of DFP-10917 combined with Venetoclax (VTX) in the AML patients pretreated by VTX involved one regimen

Retrieved on: 
Monday, March 11, 2024
Oncology, Health, FDA, Hospitals, Clinical Trials, Pharmaceutical, Biotechnology, VTX, Phase, Patient, Survival, Cancer, Hospital, Acute myeloid leukemia, AML, Pharmaceutical industry

in 2024, we are excited to share our latest development status.

Key Points: 
  • in 2024, we are excited to share our latest development status.
  • FDA submission of the protocol of the Phase I/II study of DFP-10917 combined with Venetoclax (VTX) in the AML patients pretreated by VTX involved one regimen have been done on March 8th, 2024.
  • The Phase I/II study of DFP-10917 with VTX in the above AML patients shall be started at Wake Forest and the other hospitals soon after FDA approval.
  • The invention with the combination of DFP-14927 with VTX in AML was granted in Japan, US, and Taiwan.

Rigel Announces Publication of Data on REZLIDHIA® (Olutasidenib) in Post-Venetoclax Patients with Mutant IDH1 AML in Leukemia & Lymphoma

Retrieved on: 
Thursday, April 4, 2024
Platelet transfusion, CRi, CRC, Patient, Rigel, SAN, CRH, AML, Pharmaceutical industry

"Venetoclax in combination with a hypomethylating agent is currently standard treatment for patients with newly diagnosed AML who are unfit for intensive chemotherapy, including those with mIDH1.

Key Points: 
  • "Venetoclax in combination with a hypomethylating agent is currently standard treatment for patients with newly diagnosed AML who are unfit for intensive chemotherapy, including those with mIDH1.
  • "The findings from these analyses suggest that REZLIDHIA may provide an effective treatment for patients with AML following failure of venetoclax combination therapy.
  • "These data support REZLIDHIA's efficacy and well-characterized safety profile in patients with mIDH1 R/R AML who had previously been treated with venetoclax combination regimens," said Raul Rodriguez, Rigel's president and CEO.
  • Both patients with CRi at study entry achieved CR
    Median time to CRc was 1.9 months (range 1-2.8).

Royer Cooper Cohen Braunfeld and 3iCO, LLC Launch Joint Venture

Retrieved on: 
Wednesday, April 3, 2024
Risk management, Partner (business rank), AML, General counsel, Knowledge, Senior counsel, CCO, Private law, Conshohocken, Pennsylvania, FINRA, Financial adviser

PHILADELPHIA, April 3, 2024 /PRNewswire-PRWeb/ -- Royer Cooper Cohen Braunfeld LLC (RCCB), a law firm offering a distinctive combination of practical business acumen, legal expertise and entrepreneurial passion, today announced a joint venture between the firm's partners and 3iCO, LLC, a provider of compliance consulting and outsourced Chief Compliance Officer (CCO) services. This new venture enables RCCB to cater more efficiently to regulatory compliance matters for its investment management, fund, and broker-dealer clients.

Key Points: 
  • This new venture enables RCCB to cater more efficiently to regulatory compliance matters for its investment management, fund, and broker-dealer clients.
  • RCCB's Managing Partner, John E. Royer, Jr., will serve as 3iCO's Chairman, while RCCB co-founder, Roger J. Braunfeld, will also serve on the Board with Laura and Justin.
  • Additionally, this joint venture provides another layer of expertise to which we can refer applicable clients as needs arise."
  • "I am thrilled to launch this joint venture with RCCB," said Flanagan.

Alessa Inc. and RZOLUT Join Forces to Provide Innovative Data, Compliance and Financial Crime Prevention Solutions

Retrieved on: 
Tuesday, April 2, 2024
Organization, Watchlist, Risk management, AML, Partnership, Risk, Regulatory technology, AI, PEP, Cryptocurrency

This collaboration harnesses the strengths and resources of both organizations to deliver cutting-edge data and AML compliance solutions for greater insights for regulatory compliance.

Key Points: 
  • This collaboration harnesses the strengths and resources of both organizations to deliver cutting-edge data and AML compliance solutions for greater insights for regulatory compliance.
  • Integrating RZOLUT's data with Alessa's end-to-end AML/KYC compliance solution ensures customers can identify and resolve risk in real-time at a reduced cost.
  • Additionally, Alessa clients can now directly leverage RZOLUT Due Diligence, an advanced digital platform offering various report types, from Quick Screen to Enhanced Due Diligence.
  • Alessa and RZOLUT share a vision of a risk-free world, and we are excited to build this partnership with them."

TaxBit Announces European Expansion Amidst Increasing Demand for Digital Asset Compliance Solutions

Retrieved on: 
Tuesday, April 2, 2024
AML, Partnership, Policy, Cryptocurrency

NEW YORK, April 2, 2024 /PRNewswire/ -- TaxBit, the industry leader in digital asset tax and accounting solutions, announced its strategic expansion into Europe in response to rapidly increasing adoption across the European digital asset market. This move follows recent regulatory developments and the increased demand for TaxBit's tax and accounting compliance solutions.

Key Points: 
  • NEW YORK, April 2, 2024 /PRNewswire/ -- TaxBit, the industry leader in digital asset tax and accounting solutions, announced its strategic expansion into Europe in response to rapidly increasing adoption across the European digital asset market.
  • TaxBit Announces European Expansion and welcomes Dr. Max Bernt as Managing Director of Europe.
  • "Europe has led the way in providing regulatory clarity for payments and digital asset innovation," says TaxBit CEO Lindsey Argalas.
  • For more detailed information on TaxBit's DAC7, CESOP, and IFRS Compliance Solutions, please visit taxbit.com and discover how TaxBit continues revolutionizing the digital asset compliance landscape globally.

TaxBit Announces European Expansion Amidst Increasing Demand for Digital Asset Compliance Solutions

Retrieved on: 
Tuesday, April 2, 2024
AML, Partnership, Policy, Cryptocurrency

NEW YORK, April 2, 2024 /PRNewswire/ -- TaxBit, the industry leader in digital asset tax and accounting solutions, announced its strategic expansion into Europe in response to rapidly increasing adoption across the European digital asset market. This move follows recent regulatory developments and the increased demand for TaxBit's tax and accounting compliance solutions.

Key Points: 
  • NEW YORK, April 2, 2024 /PRNewswire/ -- TaxBit, the industry leader in digital asset tax and accounting solutions, announced its strategic expansion into Europe in response to rapidly increasing adoption across the European digital asset market.
  • This move follows recent regulatory developments and the increased demand for TaxBit's tax and accounting compliance solutions.
  • "Europe has led the way in providing regulatory clarity for payments and digital asset innovation," says TaxBit CEO Lindsey Argalas.
  • For more detailed information on TaxBit's DAC7, CESOP, and IFRS Compliance Solutions, please visit taxbit.com and discover how TaxBit continues revolutionizing the digital asset compliance landscape globally.

Sumsub and Mercuryo Release Comprehensive Guide for Cryptocurrency Providers to Navigate Travel Rule Compliance

Retrieved on: 
Thursday, March 28, 2024
Web3, Organization, Environment, AML, Partnership, Travel, European, Ecosystem, Financial Action Task Force, FATF, CTF, Cryptocurrency

LONDON, March 28, 2024 /PRNewswire/ -- Sumsub, a full-cycle verification provider, has teamed up with Mercuryo, a global payments infrastructure platform, to publish a detailed guide for Virtual Asset Service Providers (VASPs), titled "Mastering Travel Rule Compliance". The guide covers everything businesses in the digital token space need to know about the Travel Rule and how to implement it effectively to stay compliant.

Key Points: 
  • LONDON, March 28, 2024 /PRNewswire/ -- Sumsub , a full-cycle verification provider, has teamed up with Mercuryo , a global payments infrastructure platform, to publish a detailed guide for Virtual Asset Service Providers (VASPs), titled " Mastering Travel Rule Compliance ".
  • Addressing the Travel Rule is critical to integrating cryptocurrency into the existing financial landscape and maintaining a secure, accountable and compliant environment.
  • Last year, Sumsub and Mercuryo released an onboarding guide for cryptocurrency businesses to help them build effective user verification in the Web3 space and resolve compliance issues.
  • To download the comprehensive "Mastering Travel Rule Compliance" guide that Sumsub and Mercuryo published today, please visit https://sumsub.com/mastering-travel-rule-guide-2024/
    To learn more about Sumsub's Travel Rule solution and book a demo, please go to https://sumsub.com/travel-rule/

CASI PHARMACEUTICALS ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2023 BUSINESS AND FINANCIAL RESULTS

Retrieved on: 
Thursday, March 28, 2024
Agreement, Transplant, CASI Pharmaceuticals, CASI, Patient, Travel, PTCL, Immunoglobulin G, CMC, Depreciation, Bone marrow, Therapy, VCP, Marketing, Research, Cleave, Pralatrexate, MCL, Rituximab, AML, Pembrolizumab, Trial of the century, Myelodysplastic syndrome, Melphalan, MDS, Clinical trial, Follicular lymphoma, Republic, Multiple myeloma, Acute myeloid leukemia, Annual report, National Medical Products Administration, Haematopoietic system, FDA, Cayman, CD19, NMPA, COVID-19, CTA, HKIAC, NHL, Non-Hodgkin lymphoma, MICL, Pharmaceutical industry

BEIJING, March 28, 2024 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a Cayman incorporated biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today reported business and financial results for the year ended December 31, 2023, and provided an update on key highlights for 2023.

Key Points: 
  • BEIJING, March 28, 2024 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a Cayman incorporated biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today reported business and financial results for the year ended December 31, 2023, and provided an update on key highlights for 2023.
  • CASI reported fourth quarter 2023 revenue of $6.9 million for EVOMELA®, 33% lower than the same period in 2022.
  • 2023 marks a major milestone for CASI and our partner Juventas; Inaticabtagene Autoleucel (CNCT-19 CAR-T cell therapy) was approved by National Medical Products Administration (NMPA) in November 2023.
  • As of December 31, 2023, CASI had cash, cash equivalents and short term investment of $29.1 million compared to $48.6 million as of December 31, 2022.

Bitget Research Report Unveils 1.5 Million Daily Active Crypto Traders in Western European

Retrieved on: 
Thursday, March 28, 2024
Research, DEX, SUI, Attention, Uniswap, CEX, Growth, FTM, Elis James, Ordinal, Bitget, AML, American Music Awards, Education, KYC, News, Non-fungible token, MetaMask, Investment, Decentralized finance, European, Nifedipine, Cryptocurrency

The number of local daily crypto traders ranges from 1.2 million to 1.5 million.

Key Points: 
  • The number of local daily crypto traders ranges from 1.2 million to 1.5 million.
  • Austria witnessed the fastest growth in crypto traders between December 2022 to December 2023, with a 70% increase in users.
  • Regional users demonstrate high participation in decentralized projects, NFTs and Web3 platforms, and active engagement in popular chain ecosystems like Solana.
  • Western European countries, characterized by developed economies and high general education levels, rank among the regions with the highest cryptocurrency adoption globally.